⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11033825 | 0.80 | GAA (0.51) | — | |
| SCHEMBL1664386 | 0.78 | — | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL317725 | 0.78 | — | — | |
| SCHEMBL4965306 | 0.77 | — | — | |
| SCHEMBL890216 | 0.76 | — | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL27485308 | 0.76 | NPC1 (0.52) | — | |
| SCHEMBL826324 | 0.76 | — | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL27473022 | 0.76 | — | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL1662601 | 0.76 | — | — | |
| 4-Imidazolecarboxylic Acid SCHEMBL27484959 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278329-B2 | Antagonizing N-type calcium channels; use as analgesic, neurodegenerative diseases, brain injury, bronchial asthma, unstable angina and irritable colitis, drug withdrawal symptoms; t-butyl 2-[4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-piperidinyl]-2-oxoethylcarbamate for example | AJINOMOTO CO., INC. (JP) | 2012-10-02 | — | — | US | claimed |
| US-7713957-B2 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | AJINOMOTO CO., INC. (JP) | 2010-05-11 | — | — | US | claimed |
| US-7462630-B2 | Diarylalkene derivatives and novel diarylalkane derivatives | AJINOMOTO CO., INC. (JP) | 2008-12-09 | — | — | US | claimed |
| US-20080058311-A1 | NOVEL DIARYLALKENE DERIVATIVES AND NOVEL DIARYLALKANE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2008-03-06 | — | — | US | claimed |
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | AJINOMOTO CO., INC. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1481673-A1 | MEDICINAL COMPOSITIONS CONTAINING GABAPENTIN OR PREGABALIN AND N-TYPE CALCIUM CHANNEL ANTAGONIST | Ajinomoto Co., Inc. (JP) | 2004-12-01 | — | — | EP | claimed |
| US-20040167118-A1 | Novel diarylalkene derivatives and novel diarylalkane derivatives | AJINOMOTO CO., INC. (JP) | 2004-08-26 | — | — | US | claimed |
| US-8481558-B2 | Compounds to inhibit or augment an inflammatory response | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8278329-B2 | Antagonizing N-type calcium channels; use as analgesic, neurodegenerative diseases, brain injury, bronchial asthma, unstable angina and irritable colitis, drug withdrawal symptoms; t-butyl 2-[4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-piperidinyl]-2-oxoethylcarbamate for example | AJINOMOTO CO., INC. (JP) | 2012-10-02 | — | — | US | disclosed |
| US-20120065401-A1 | METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| EP-2386565-A2 | Compounds and methods to inhibit or augment an inflammatory response | Cambridge Enterprise Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-7989466-B2 | Administering chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs to modulate the migration or recruitment of leukocytes to a preselected physiological site | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-08-02 | — | — | US | disclosed |
| US-7713957-B2 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | AJINOMOTO CO., INC. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | AJINOMOTO CO., INC. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1481673-A1 | MEDICINAL COMPOSITIONS CONTAINING GABAPENTIN OR PREGABALIN AND N-TYPE CALCIUM CHANNEL ANTAGONIST | Ajinomoto Co., Inc. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040167118-A1 | Novel diarylalkene derivatives and novel diarylalkane derivatives | AJINOMOTO CO., INC. (JP) | 2004-08-26 | — | — | US | disclosed |
| EP-1141011-A2 | COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | NEORX CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000042071-A2 | COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB) | 2000-07-20 | — | — | WO | disclosed |
| EP-1012187-A2 | CHEMOKINE PEPTIDES, VARIANTS, DERIVATIVES AND ANALOGS. THEIR USE IN METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | NEORX CORPORATION (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999012968-A2 | CHEMOKINE PEPTIDES, VARIANTS, DERIVATIVES AND ANALOGS, THEIR USE IN METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE | NEORX CORPORATION (US) | 1999-03-18 | — | — | WO | disclosed |